Skip to main content
Clinician wearing a facemask administering a vaccination to a male patient

Global HIV Vaccine Enterprise

AIM: To share knowledge, foster collaboration, enable solutions and expand support critical to the development of – and future access to – an HIV vaccine

Established in 2003, the Global HIV Vaccine Enterprise became a programme of the IAS in 2018. It works to engage stakeholders and funders to accelerate HIV vaccine development and prepare the field for the future discovery of a safe, effective and globally accessible HIV vaccine.

It does so by: 

  • Strengthening the HIV vaccine pipeline by encouraging diverse approaches in HIV vaccine research and advancing the HIV vaccine portfolio
  • Expanding and diversifying engagement and resources by fostering interest in HIV vaccine R&D and broadening research talent within the HIV vaccine field
  • Mobilizing knowledge to accelerate product development by driving opportunities to address unanswered scientific questions and leveraging synergies with other infectious disease research

[email protected]

With support from:

This project was sponsored by the United States National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Division of Aids (DAIDS) and administered through a grant by CRDF Global.

Related resources

alternative text

Webinars, workshops & other convenings


alternative text


Annual stakeholders’ meeting: “Accelerating early phase HIV vaccine clinical research” (November 2022)

Consistent with its strategic objectives, the Enterprise is convening HIV vaccine R&D stakeholders with the aim to build a consensus on efficient ways to prioritize and advance vaccine product development that encompasses design, clinical testing, and funding to accelerate the development of an HIV vaccine.

View more

Webinar series: Experimental Medicine for Preventative HIV Vaccines (January – September 2022)

A three-part event to engage scientists, clinicians, industry, funders and community representatives on experimental medicine to progress HIV vaccine development efforts.

  • Webinar 01 - What is Experimental Medicine and what are the key challenges? (January 2022)
  • Webinar 02 - Experimental Medicine trials for HIV vaccine research (February 2022)
  • Webinar 03 - Building regulatory and ethics expertise for Experimental Medicine (September 2022)

View more

Webinar series: Engaging adolescent girls and young women in HIV prevention research (August – September 2022)

This two-part webinar series will highlight the key aspects related to the ethics of engaging adolescent girls and young women in HIV prevention research and sexual and reproductive health programming, and leverage insights from social and behavioural research to inform future design of engagement strategies for this group.

  • Webinar 01 - Engaging Adolescent Girls and Young Women (AGYW) in HIV prevention research (August 2022)
  • Webinar 02 - Better understanding the needs of adolescent women and young girls in HIV prevention research design (September 2022)

View more


Virtual workshop series: “Design approaches for current and future HIV prevention efficacy trials” (October 2020 – May 2021)

This series of virtual workshops aims to continue from the first HIV Prevention Efficacy Trial Designs of the Future symposium, which was held in Seattle by the Fred Hutch and the NIAID in November 2018.

Participants will reflect on more recent advances and challenges within the HIV prevention field and on the rationale and lessons learnt for current HIV prevention designs. They will examine novel scientific approaches for establishing efficacy of new biologics in a future where all trial participants have access to effective prevention.

  • Session 01 - Current efficacy trial design approaches – challenges and lessons learned (October 2020)
  • Session 02 - Future efficacy trial design approaches (November 2020)
  • Session 03 - Future efficacy trial design approaches (May 2021)

View more


Webinar: Making Monoclonal Antibodies Broadly Accessible to Communities Most At Risk Of HIV/AIDS – What Would It Take? (November 2020)

This webinar organized in partnership with IAVI will discuss challenges and opportunities in access to future monoclonal antibodies for HIV prevention.

View more


alternative text